drugset / Trial / NCT01269047
Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
Phase 4
Completed
37 enrolled
Albert Einstein College of Medicine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of the study is to determine the effects of 16 weeks of adjunctive pramlintide or exenatide use on glycemic control in Type 1 Diabetes.
Timeline
- Start
- 2009-08
- Primary completion
- 2016-08
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exenatide | Peptide | 2.5 ug | Subcutaneous |
| Subject | Exenatide | Peptide | 5 ug | Subcutaneous |
| Subject | Pramlintide | Peptide | 60 ug | Subcutaneous |
| Comparator | Insulin | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | Insulin Lispro | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | insulin aspart | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | insulin glargine | Protein / enzyme biologic | — | Subcutaneous |